PF-06651600 for the Treatment of Alopecia Areata

A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03732807

Acronym

ALLEGRO-2b/3

Enrollment

718

Registered

2018-11-07

Start date

2018-12-03

Completion date

2021-06-24

Last updated

2022-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia Areata

Keywords

Alopecia, Alopecia totalis, Alopecia universalis, Patchy hair loss, Diffuse hair loss, Hair loss, Hair disease, PF-06651600, Ritlecitinib

Brief summary

This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 5 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.

Interventions

DRUGPF-06651600 Induction Dose

Oral tablets taken once daily (QD)

DRUGPF-06651600 Maintenance Dose #1

Oral tablets taken QD

DRUGPF-06651600 Maintenance Dose #2

Oral tablets taken QD

DRUGPF-06651600 Maintenance Dose #3

Oral tablets taken QD

DRUGPlacebo

Oral tablets taken QD

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of alopecia areata with no other cause of hair loss * ≥50% hair loss of the scalp, including alopecia totalis and alopecia universalis, without evidence of terminal hair regrowth within 6 months * Current episode of hair loss ≤10 years

Exclusion criteria

* Other types of alopecia or other diseases that can cause hair loss * Other scalp diseases that could interfere with assessment of hair loss/regrowth * Subjects with shaved heads must not enter the study until hair has grown back & is considered stable by the investigator * Any previous use of any Janus kinase (JAK) inhibitor

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24	Week 24	SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score less than or equal to (\<=) 20 at week 24 were reported.

Secondary

Measure	Time frame	Description
Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 4, 8, 12, 18, 28, 34, 40, and 48	SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.
Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	EBA is a numeric rating scale developed to characterize eyebrow hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where, 0= no eyebrow, 1=minimal eyebrow, 2=moderate eyebrow and 3= normal eyebrow, where higher scores represent less hair loss of eyebrows.
Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	ELA is a numeric rating scale developed to characterize eyelash hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where, 0=no eyelash, 1=minimal eyelash, 2=moderate eyelash and 3=normal eyelash, where higher scores represent less hair loss of eyelash.
Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4, 8, 12, 18, 24, 34, 40, and 48	PGI-C is a self-administered questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. PGI-C was assessed on a 7-point Likert scale ranged from 1 (greatly improved) to 7 (greatly worsened). Categories were defined based on the PGI-C scores as follows: 1=greatly improved, 2=moderately improved, 3=slightly improved, 4=not changed, 5=slightly worsened, 6=moderately worsened and 7=greatly worsened.
Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Baseline (Day 1), Week 4, 8, 12, 18, and 24	AAPPO scale is 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss'. Items 5-8 assessed emotional symptoms. Response choices on these items were scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations. Response choices on these items were scored from 0='not at all' to 4='completely'. Change from baseline in AAPPO emotional symptoms sub score were calculated as mean of items 5-8 and ranged from 0(never) to 4(always), where higher scores indicated more emotional symptoms. Change from baseline in AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. Baseline was defined as pre-dose on Day 1.
Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Baseline (Day 1), Week 34, 40, and 48	AAPPO scale is 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss'. Items 5-8 assessed emotional symptoms. Response choices on these items were scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations. Response choices on these items were scored from 0='not at all' to 4='completely'. Change from baseline in AAPPO emotional symptoms sub score were calculated as mean of items 5-8 and ranged from 0(never) to 4(always), where higher scores indicated more emotional symptoms. Change from baseline in AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. Baseline was defined as pre-dose on Day 1.
Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4, 8, 12, 18, 24, 34, 40, and 48	AAPPO scale is a 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over the past week. Items 1-4 were to assess the current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on a scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss', where higher scores indicated more hair loss.
Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4	Week 24	SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<= 10 at week 24 were reported.
Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1	Week 24	SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<= 10 at week 24 were reported.
Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24	Week 24	PGI-C is a self-administered questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. PGI-C was assessed on a 7-point Likert scale ranged from 1 (greatly improved) to 7 (greatly worsened). Categories were defined based on the PGI-C scores as follows: 1=greatly improved, 2=moderately improved, 3=slightly improved, 4=not changed, 5=slightly worsened, 6=moderately worsened and 7=greatly worsened.
Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model	Week 24	The exposure response of Ritlecitinib (PF-06651600) on the regrowth of scalp hair was characterized using a Bayesian three-parameter hyperbolic Emax model for the SALT score \<=20 at Week 24 with an additional term for effect of loading dose. In Emax exposure-response model the response function was the log odds of the percentage of participants with response based on SALT \<=20 at Week 24, which was fit on the logistic scale and then back-transformed to percentage. The effect of loading dose is included as fixed factor in the model. The variable that represents loading dose has values of 1 for groups 200/50 mg once daily and 200/30 mg once daily and of 0 for the remaining groups. SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.
Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model	Week 24	The exposure response of Ritlecitinib (PF-06651600) on the regrowth of scalp hair was characterized using a Bayesian three-parameter hyperbolic Emax model for the SALT score \<=10 at Week 24 with an additional term for effect of loading dose. In Emax exposure-response model the response function was the log odds of the percentage of participants with response based on SALT \<=10 at Week 24, which was fit on the logistic scale and then back-transformed to percentage. The effect of loading dose is included as fixed factor in the model. The variable that represents loading dose has values of 1 for groups 200/50 mg once daily and 200/30 mg once daily and of 0 for the remaining groups. SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.
Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 4, 8, 12, 18, 28, 34, 40, and 48	SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<=10 were reported.
Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. A SALT 75 response was a 75% or greater reduction from baseline in SALT score.
Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Baseline (Day 1), Week 4, 8, 12, 18, and 24	SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. Baseline was defined as pre-dose on Day 1.
Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Baseline (Day 1), Week 28, 34, 40, and 48	SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. Baseline was defined as pre-dose on Day 1.

Other

Measure	Time frame	Description
Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Baseline (Day 1), Week 4, 8, 12, and 24	HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for anxiety subscale; higher score indicating greater severity of anxiety symptoms. Baseline was defined as pre-dose on Day 1.
Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Baseline (Day 1), Week 48	HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for anxiety subscale; higher score indicating greater severity of anxiety symptoms. Baseline was defined as pre-dose on Day 1.
Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 4, 8, 12, 24 and 48	HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms.
Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 4, 8, 12, 24 and 48	HADS is a validated 14-item PRO measure used to assessed states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for anxiety subscale; higher score indicating greater severity of anxiety symptoms.
Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Baseline (Day 1), Week 48	HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms. Baseline was defined as pre-dose on Day 1.
Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Baseline (Day 1), Week 4, 8, 12, and 24	HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms. Baseline was defined as pre-dose on Day 1.

Countries

Argentina, Australia, Canada, Chile, China, Colombia, Czechia, Germany, Hungary, Japan, Mexico, Poland, Russia, South Korea, Spain, Taiwan, United Kingdom, United States

Participant flow

Pre-assignment details

Total 1097 participants signed the informed consent form. Out of which 379 participants were screen failures, 718 actually enrolled into the study and were assigned to study treatments.

Participants by arm

Arm	Count
Ritlecitinib (PF-06651600) 200 mg Then 50 mg Participants aged 12 years or above with moderate to severe AA with \>=50% hair loss of the scalp were randomized to receive Ritlecitinib 4 of 50 mg tablet once daily for 4 weeks (loading phase) and then 50 mg tablet once daily for next 20 weeks (maintenance phase). Participants then entered into extension phase of 24 weeks and continued to receive 50 mg tablet once daily. Participants were followed up to maximum of 5 weeks after the last dose of study drug .	132
Ritlecitinib (PF-06651600) 200 mg Then 30 mg Participants aged 12 years or above with moderate to severe AA with \>=50% hair loss of the scalp were randomized to receive Ritlecitinib 4 of 50 mg tablet once daily for 4 weeks (loading phase) and then 3 of 10 mg tablet once daily for next 20 weeks (maintenance phase). Participants then entered into extension phase of 24 weeks and continued to receive 3 of 10 mg tablet once daily. Participants were followed up to maximum of 5 weeks after the last dose of study drug.	130
Ritlecitinib (PF-06651600) 50 mg Participants aged 12 years or above with moderate to severe AA with \>=50% hair loss of the scalp were randomized to receive Ritlecitinib 50 mg tablet once daily for 4 weeks (loading phase). Participants then continued to receive 50 mg tablet once daily in maintenance phase of 20 weeks and extension phase of 24 weeks. Participants were followed up to maximum of 5 weeks after the last dose of study drug.	130
Ritlecitinib (PF-06651600) 30 mg Participants aged 12 years or above with moderate to severe AA with \>=50% hair loss of the scalp were randomized to receive Ritlecitinib 3 of 10 mg tablet once daily for 4 weeks (loading phase). Participants then continued to receive 3 of 10 mg tablet once daily in maintenance phase of 20 weeks and extension phase of 24 weeks. Participants were followed up to maximum of 5 weeks after the last dose of study drug.	132
Ritlecitinib (PF-06651600) 10 mg Participants aged 12 years or above with moderate to severe AA with \>=50% hair loss of the scalp were randomized to receive Ritlecitinib 10 mg tablet once daily for 4 weeks (loading phase). Participants then continued to receive 10 mg tablet once daily in maintenance phase of 20 weeks and extension phase of 24 weeks. Participants were followed up to maximum of 5 weeks after the last dose of study drug.	63
Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg Participants aged 12 years or above with moderate to severe AA with \>=50% hair loss of the scalp were randomized to receive placebo once daily for 4 weeks (loading phase) and then continued placebo once daily for next 20 weeks (maintenance phase). Participants then entered into extension phase of 24 weeks and received 4 of 50 mg tablet once daily for 4 weeks and then 50 mg tablet once daily for 20 weeks. Participants were followed up to maximum of 5 weeks after the last dose of study drug.	65
Placebo, Ritlecitinib (PF-06651600) 50 mg Participants aged 12 years or above with moderate to severe AA with \>=50% hair loss of the scalp were randomized to receive placebo once daily for 4 weeks (loading phase) and then continued to receive placebo once daily for next 20 weeks (maintenance phase). Participants then entered into extension phase of 24 weeks and received 50 mg tablet once daily. Participants were followed up to maximum of 5 weeks after the last dose of study drug.	66
Total	718

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005	FG006
Treatment Extension (Week 25 up to 48)	Adverse Event	0	2	2	1	0	0	2
Treatment Extension (Week 25 up to 48)	Lack of Efficacy	2	1	0	3	3	0	1
Treatment Extension (Week 25 up to 48)	Lost to Follow-up	0	0	2	1	1	2	0
Treatment Extension (Week 25 up to 48)	Non-Compliant with study drug	0	1	0	0	0	0	0
Treatment Extension (Week 25 up to 48)	Other	1	4	0	2	0	0	0
Treatment Extension (Week 25 up to 48)	Physician Decision	0	1	0	1	1	0	0
Treatment Extension (Week 25 up to 48)	Withdrawal by Subject	3	2	1	1	0	1	1
Treatment Period (up to Week 24)	Adverse Event	3	0	2	4	2	0	1
Treatment Period (up to Week 24)	Lack of Efficacy	0	0	0	0	0	1	0
Treatment Period (up to Week 24)	Lost to Follow-up	1	0	1	2	1	0	0
Treatment Period (up to Week 24)	Physician Decision	0	1	2	5	0	0	1
Treatment Period (up to Week 24)	Pregnancy	1	0	0	0	1	0	1
Treatment Period (up to Week 24)	Protocol Violation	1	1	0	0	0	0	0
Treatment Period (up to Week 24)	Withdrawal by Subject	4	4	4	4	1	1	2

Baseline characteristics

Characteristic	Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Ritlecitinib (PF-06651600) 50 mg	Ritlecitinib (PF-06651600) 30 mg	Ritlecitinib (PF-06651600) 10 mg	Placebo, Ritlecitinib (PF-06651600) 50 mg	Total
Age, Continuous	33.0 Years STANDARD_DEVIATION 14.01	34.5 Years STANDARD_DEVIATION 14.98	33.7 Years STANDARD_DEVIATION 13.75	32.4 Years STANDARD_DEVIATION 13.36	33.7 Years STANDARD_DEVIATION 14.83	34.3 Years STANDARD_DEVIATION 13.88	35.0 Years STANDARD_DEVIATION 15.89	33.8 Years STANDARD_DEVIATION 14.33
Ethnicity (NIH/OMB) Hispanic or Latino	7 Participants	18 Participants	16 Participants	11 Participants	23 Participants	8 Participants	4 Participants	87 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	58 Participants	113 Participants	114 Participants	116 Participants	109 Participants	55 Participants	61 Participants	626 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	1 Participants	0 Participants	3 Participants	0 Participants	0 Participants	1 Participants	5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	1 Participants	0 Participants	2 Participants	0 Participants	0 Participants	3 Participants
Race (NIH/OMB) Asian	14 Participants	33 Participants	28 Participants	43 Participants	34 Participants	17 Participants	17 Participants	186 Participants
Race (NIH/OMB) Black or African American	2 Participants	6 Participants	7 Participants	5 Participants	3 Participants	2 Participants	2 Participants	27 Participants
Race (NIH/OMB) More than one race	2 Participants	0 Participants	3 Participants	1 Participants	2 Participants	0 Participants	0 Participants	8 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	1 Participants	1 Participants	2 Participants	0 Participants	1 Participants	0 Participants	5 Participants
Race (NIH/OMB) White	47 Participants	92 Participants	90 Participants	79 Participants	91 Participants	42 Participants	47 Participants	488 Participants
Sex: Female, Male Female	46 Participants	81 Participants	85 Participants	71 Participants	80 Participants	43 Participants	40 Participants	446 Participants
Sex: Female, Male Male	19 Participants	51 Participants	45 Participants	59 Participants	52 Participants	20 Participants	26 Participants	272 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk
deaths Total, all-cause mortality	0 / 131	0 / 129	0 / 130	0 / 132	0 / 62	0 / 65	0 / 66
other Total, other adverse events	84 / 131	76 / 129	81 / 130	77 / 132	32 / 62	39 / 65	39 / 66
serious Total, serious adverse events	4 / 131	2 / 129	2 / 130	1 / 132	2 / 62	0 / 65	3 / 66

Outcome results

Primary

Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24

SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score less than or equal to (\<=) 20 at week 24 were reported.

Time frame: Week 24

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Participants with missing SALT scores due to coronavirus disease-19 related reasons were excluded from this analysis, while participants with missing data due to other reasons were considered as non-responders. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure.

Arm	Measure	Value (NUMBER)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24	30.65 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24	22.31 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24	23.39 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24	14.29 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24	1.69 Percentage of participants
Placebo	Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24	1.54 Percentage of participants

p-value: <0.00000195% CI: [21.17, 37.91]Miettinen and Nurminen method

p-value: <0.00000195% CI: [13.65, 29.18]Miettinen and Nurminen method

p-value: <0.00000195% CI: [14.65, 30.23]Miettinen and Nurminen method

p-value: 0.00015495% CI: [6.69, 20.36]Miettinen and Nurminen method

Secondary

Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations

AAPPO scale is 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss'. Items 5-8 assessed emotional symptoms. Response choices on these items were scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations. Response choices on these items were scored from 0='not at all' to 4='completely'. Change from baseline in AAPPO emotional symptoms sub score were calculated as mean of items 5-8 and ranged from 0(never) to 4(always), where higher scores indicated more emotional symptoms. Change from baseline in AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. Baseline was defined as pre-dose on Day 1.

Time frame: Baseline (Day 1), Week 34, 40, and 48

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specified time point.

Arm	Measure	Group	Value (MEAN)	Dispersion
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 34: activity limitations	-0.37 Units on a scale	Standard Deviation 0.71
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 48: emotional symptoms	-0.96 Units on a scale	Standard Deviation 0.99
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 40: activity limitations	-0.44 Units on a scale	Standard Deviation 0.76
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 48: activity limitations	-0.43 Units on a scale	Standard Deviation 0.79
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 34: emotional symptoms	-0.78 Units on a scale	Standard Deviation 0.95
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 40: emotional symptoms	-0.84 Units on a scale	Standard Deviation 1.04
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 34: emotional symptoms	-0.72 Units on a scale	Standard Deviation 1
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 40: activity limitations	-0.33 Units on a scale	Standard Deviation 0.84
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 34: activity limitations	-0.31 Units on a scale	Standard Deviation 0.78
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 48: emotional symptoms	-0.84 Units on a scale	Standard Deviation 1.07
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 48: activity limitations	-0.39 Units on a scale	Standard Deviation 0.84
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 40: emotional symptoms	-0.80 Units on a scale	Standard Deviation 1.02
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 34: activity limitations	-0.26 Units on a scale	Standard Deviation 0.73
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 48: emotional symptoms	-0.85 Units on a scale	Standard Deviation 1.04
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 40: emotional symptoms	-0.81 Units on a scale	Standard Deviation 0.98
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 34: emotional symptoms	-0.72 Units on a scale	Standard Deviation 0.93
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 40: activity limitations	-0.25 Units on a scale	Standard Deviation 0.68
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 48: activity limitations	-0.29 Units on a scale	Standard Deviation 0.76
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 40: activity limitations	-0.42 Units on a scale	Standard Deviation 0.81
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 48: activity limitations	-0.36 Units on a scale	Standard Deviation 0.85
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 34: emotional symptoms	-0.71 Units on a scale	Standard Deviation 1.06
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 40: emotional symptoms	-0.83 Units on a scale	Standard Deviation 1.11
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 48: emotional symptoms	-0.72 Units on a scale	Standard Deviation 1.15
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 34: activity limitations	-0.37 Units on a scale	Standard Deviation 0.78
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 40: activity limitations	-0.23 Units on a scale	Standard Deviation 0.71
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 40: emotional symptoms	-0.62 Units on a scale	Standard Deviation 0.96
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 34: activity limitations	-0.33 Units on a scale	Standard Deviation 0.76
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 48: emotional symptoms	-0.50 Units on a scale	Standard Deviation 0.89
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 34: emotional symptoms	-0.62 Units on a scale	Standard Deviation 0.83
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 48: activity limitations	-0.26 Units on a scale	Standard Deviation 0.9
Placebo	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 48: activity limitations	-0.44 Units on a scale	Standard Deviation 0.71
Placebo	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 34: activity limitations	-0.36 Units on a scale	Standard Deviation 0.59
Placebo	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 40: emotional symptoms	-0.83 Units on a scale	Standard Deviation 1.01
Placebo	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 40: activity limitations	-0.40 Units on a scale	Standard Deviation 0.66
Placebo	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 48: emotional symptoms	-0.98 Units on a scale	Standard Deviation 1.05
Placebo	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 34: emotional symptoms	-0.77 Units on a scale	Standard Deviation 0.92
Placebo, Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 40: activity limitations	-0.39 Units on a scale	Standard Deviation 0.84
Placebo, Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 40: emotional symptoms	-0.66 Units on a scale	Standard Deviation 1
Placebo, Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 34: activity limitations	-0.42 Units on a scale	Standard Deviation 0.78
Placebo, Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 34: emotional symptoms	-0.64 Units on a scale	Standard Deviation 0.91
Placebo, Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 48: activity limitations	-0.36 Units on a scale	Standard Deviation 0.81
Placebo, Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations	Change at Week 48: emotional symptoms	-0.68 Units on a scale	Standard Deviation 1.03

Secondary

Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations

Time frame: Baseline (Day 1), Week 4, 8, 12, 18, and 24

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specified time point.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 18: emotional symptoms	-0.64 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 12: emotional symptoms	-0.53 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 24: activity limitations	-0.30 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 18: activity limitations	-0.35 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 12: activity limitations	-0.27 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 8: activity limitations	-0.24 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 8: emotional symptoms	-0.50 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 4: emotional symptoms	-0.37 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 4: activity limitations	-0.19 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 24: emotional symptoms	-0.61 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 8: emotional symptoms	-0.46 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 4: emotional symptoms	-0.22 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 12: emotional symptoms	-0.54 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 18: emotional symptoms	-0.57 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 24: emotional symptoms	-0.61 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 4: activity limitations	-0.04 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 8: activity limitations	-0.25 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 12: activity limitations	-0.22 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 18: activity limitations	-0.26 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 24: activity limitations	-0.30 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 18: emotional symptoms	-0.60 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 12: activity limitations	-0.21 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 4: emotional symptoms	-0.33 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 24: emotional symptoms	-0.69 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 12: emotional symptoms	-0.48 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 8: emotional symptoms	-0.50 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 4: activity limitations	-0.16 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 18: activity limitations	-0.23 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 24: activity limitations	-0.31 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 8: activity limitations	-0.18 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 8: activity limitations	-0.09 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 12: activity limitations	-0.24 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 8: emotional symptoms	-0.36 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 24: activity limitations	-0.28 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 18: activity limitations	-0.23 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 4: emotional symptoms	-0.31 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 4: activity limitations	-0.13 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 24: emotional symptoms	-0.58 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 18: emotional symptoms	-0.54 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 12: emotional symptoms	-0.49 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 8: activity limitations	-0.21 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 18: emotional symptoms	-0.44 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 24: emotional symptoms	-0.49 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 4: activity limitations	-0.20 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 4: emotional symptoms	-0.29 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 12: activity limitations	-0.27 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 24: activity limitations	-0.31 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 18: activity limitations	-0.28 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 12: emotional symptoms	-0.50 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 8: emotional symptoms	-0.45 Units on a scale
Placebo	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 4: activity limitations	-0.18 Units on a scale
Placebo	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 24: activity limitations	-0.29 Units on a scale
Placebo	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 8: emotional symptoms	-0.39 Units on a scale
Placebo	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 12: emotional symptoms	-0.36 Units on a scale
Placebo	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 24: emotional symptoms	-0.47 Units on a scale
Placebo	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 8: activity limitations	-0.20 Units on a scale
Placebo	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 18: emotional symptoms	-0.43 Units on a scale
Placebo	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 12: activity limitations	-0.21 Units on a scale
Placebo	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 4: emotional symptoms	-0.28 Units on a scale
Placebo	Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations	Change at Week 18: activity limitations	-0.26 Units on a scale

Secondary

Change From Baseline in SALT Score at Week 28, 34, 40, and 48

Time frame: Baseline (Day 1), Week 28, 34, 40, and 48

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point.

Arm	Measure	Group	Value (MEAN)	Dispersion
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 48	-49.4 Units on a scale	Standard Deviation 36.09
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Baseline	90.3 Units on a scale	Standard Deviation 15.05
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 28	-44.1 Units on a scale	Standard Deviation 36.35
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 34	-48.2 Units on a scale	Standard Deviation 36.16
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 40	-49.3 Units on a scale	Standard Deviation 36.11
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 40	-38.5 Units on a scale	Standard Deviation 37.14
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 48	-40.5 Units on a scale	Standard Deviation 37.27
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 28	-33.3 Units on a scale	Standard Deviation 33.85
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 34	-35.5 Units on a scale	Standard Deviation 35.5
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Baseline	90.5 Units on a scale	Standard Deviation 14.28
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Baseline	90.3 Units on a scale	Standard Deviation 14.69
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 34	-43.6 Units on a scale	Standard Deviation 34.35
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 48	-48.9 Units on a scale	Standard Deviation 36.63
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 28	-36.1 Units on a scale	Standard Deviation 33.42
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 40	-46.9 Units on a scale	Standard Deviation 35.68
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 40	-35.9 Units on a scale	Standard Deviation 35.9
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 48	-40.1 Units on a scale	Standard Deviation 35.87
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Baseline	90.0 Units on a scale	Standard Deviation 15.07
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 28	-29.2 Units on a scale	Standard Deviation 32.56
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 34	-33.5 Units on a scale	Standard Deviation 35.01
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Baseline	88.3 Units on a scale	Standard Deviation 16.87
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 34	-7.6 Units on a scale	Standard Deviation 23.61
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 28	-5.6 Units on a scale	Standard Deviation 23.15
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 40	-11.4 Units on a scale	Standard Deviation 26.01
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 48	-13.3 Units on a scale	Standard Deviation 30.13
Placebo	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 40	-36.5 Units on a scale	Standard Deviation 34.56
Placebo	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Baseline	94.4 Units on a scale	Standard Deviation 9.31
Placebo	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 48	-46.3 Units on a scale	Standard Deviation 35.51
Placebo	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 34	-27.5 Units on a scale	Standard Deviation 32.78
Placebo	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 28	-11.5 Units on a scale	Standard Deviation 22.75
Placebo, Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 48	-32.2 Units on a scale	Standard Deviation 32.39
Placebo, Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 34	-12.6 Units on a scale	Standard Deviation 24.47
Placebo, Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Baseline	91.5 Units on a scale	Standard Deviation 13.22
Placebo, Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 28	-5.0 Units on a scale	Standard Deviation 18.51
Placebo, Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in SALT Score at Week 28, 34, 40, and 48	Change at Week 40	-23.0 Units on a scale	Standard Deviation 30.64

Secondary

Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24

Time frame: Baseline (Day 1), Week 4, 8, 12, 18, and 24

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 8	-12.8 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 12	-22.7 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 24	-36.5 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 4	-2.3 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 18	-31.2 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 24	-29.2 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 8	-12.5 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 4	-2.7 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 18	-25.0 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 12	-20.1 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 18	-22.5 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 24	-33.3 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 12	-12.4 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 8	-6.3 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 4	-1.8 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 8	-5.0 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 18	-17.5 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 4	-1.3 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 12	-10.3 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 24	-23.6 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 8	-1.7 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 24	-4.2 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 4	-1.3 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 18	-2.4 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 12	-3.5 Units on a scale
Placebo	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 8	-1.2 Units on a scale
Placebo	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 4	-0.9 Units on a scale
Placebo	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 12	-2.4 Units on a scale
Placebo	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 24	-5.1 Units on a scale
Placebo	Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24	Change at Week 18	-3.9 Units on a scale

Secondary

Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model

The exposure response of Ritlecitinib (PF-06651600) on the regrowth of scalp hair was characterized using a Bayesian three-parameter hyperbolic Emax model for the SALT score \<=10 at Week 24 with an additional term for effect of loading dose. In Emax exposure-response model the response function was the log odds of the percentage of participants with response based on SALT \<=10 at Week 24, which was fit on the logistic scale and then back-transformed to percentage. The effect of loading dose is included as fixed factor in the model. The variable that represents loading dose has values of 1 for groups 200/50 mg once daily and 200/30 mg once daily and of 0 for the remaining groups. SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.

Time frame: Week 24

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure.

Arm	Measure	Value (NUMBER)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model	21.29 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model	13.76 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model	14.43 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model	9.02 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model	3.88 Percentage of participants
Placebo	Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model	1.66 Percentage of participants

Secondary

Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model

The exposure response of Ritlecitinib (PF-06651600) on the regrowth of scalp hair was characterized using a Bayesian three-parameter hyperbolic Emax model for the SALT score \<=20 at Week 24 with an additional term for effect of loading dose. In Emax exposure-response model the response function was the log odds of the percentage of participants with response based on SALT \<=20 at Week 24, which was fit on the logistic scale and then back-transformed to percentage. The effect of loading dose is included as fixed factor in the model. The variable that represents loading dose has values of 1 for groups 200/50 mg once daily and 200/30 mg once daily and of 0 for the remaining groups. SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.

Time frame: Week 24

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Here Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure.

Arm	Measure	Value (NUMBER)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model	32.37 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model	20.57 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model	22.52 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model	13.58 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model	4.81 Percentage of participants
Placebo	Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model	1.63 Percentage of participants

Secondary

Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1

Time frame: Week 24

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Analysis 1: Participants with missing SALT score at Week 24 due to COVID-19 related reasons excluded from analysis at that time point, participants with missing SALT scores due to other reasons counted as non-responders at that time point.

Arm	Measure	Value (NUMBER)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1	21.77 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1	13.22 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1	13.71 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1	10.92 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1	1.69 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1	1.54 Percentage of participants

p-value: <0.00000195% CI: [13.23, 28.49]Miettinen and Nurminen method

p-value: 0.00033795% CI: [5.82, 19.07]Miettinen and Nurminen method

p-value: 0.00022895% CI: [6.27, 19.53]Miettinen and Nurminen method

p-value: 0.00187595% CI: [3.86, 16.46]Miettinen and Nurminen method

Secondary

Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4

Time frame: Week 24

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Analysis 4: Data imputed by using a missing at random (MAR) mechanism for participants with missing data due to COVID-19. Missing data due to reasons not related to COVID-19 were consider as non-responders.

Arm	Measure	Value (NUMBER)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4	21.29 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4	12.87 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4	13.42 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4	10.62 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4	1.65 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4	1.54 Percentage of participants

Comparison: A generalized linear mixed effect model without imputation using observed data up to Week 24 was used as the imputation model. A single complete imputed data set for Week 24 was analyzed using the Miettinen and Nurminen method as the analysis model.p-value: <0.00000195% CI: [11.91, 27.59]Miettinen and Nurminen method

Comparison: A generalized linear mixed effect model without imputation using observed data up to Week 24 was used as the imputation model. A single complete imputed data set for Week 24 was analyzed using the Miettinen and Nurminen method as the analysis model.p-value: 0.00052695% CI: [4.93, 17.74]Miettinen and Nurminen method

Comparison: A generalized linear mixed effect model without imputation using observed data up to Week 24 was used as the imputation model. A single complete imputed data set for Week 24 was analyzed using the Miettinen and Nurminen method as the analysis model.p-value: 0.00031195% CI: [5.42, 18.33]Miettinen and Nurminen method

Comparison: A generalized linear mixed effect model without imputation using observed data up to Week 24 was used as the imputation model. A single complete imputed data set for Week 24 was analyzed using the Miettinen and Nurminen method as the analysis model.p-value: 0.00292295% CI: [3.1, 15.07]Miettinen and Nurminen method

Secondary

Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48

Time frame: Week 4, 8, 12, 18, 28, 34, 40, and 48

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point.

Arm	Measure	Group	Value (NUMBER)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 34	30.40 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 18	12.40 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 40	31.25 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 12	6.35 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 48	33.33 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 28	29.17 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 8	2.34 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 4	0.78 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 18	7.44 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 40	25.20 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 8	0.83 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 34	18.70 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 28	16.81 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 12	5.65 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 48	27.87 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 28	18.49 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 8	0.82 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 12	5.56 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 18	6.56 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 34	23.39 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 40	27.05 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 48	31.20 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 34	22.13 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 40	25.00 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 18	5.13 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 28	16.39 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 8	0.00 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 48	25.41 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 12	0.82 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 34	3.39 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 18	1.67 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 48	6.56 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 12	1.69 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 8	0.00 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 28	3.33 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 40	3.39 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 8	0.00 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 40	18.46 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 18	1.67 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 12	0.00 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 48	24.62 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 28	1.75 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 34	13.11 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 8	0.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 28	3.17 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 40	9.23 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 48	14.06 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 18	1.61 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 12	1.59 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 34	4.62 Percentage of participants

Secondary

Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48

SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.

Time frame: Week 4, 8, 12, 18, 28, 34, 40, and 48

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point.

Arm	Measure	Group	Value (NUMBER)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 12	11.90 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 34	38.40 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 8	5.47 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 4	0.78 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 28	34.17 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 40	39.06 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 48	39.53 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 18	19.83 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 18	13.22 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 12	8.87 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 40	33.33 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 34	27.64 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 48	34.43 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 28	23.53 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 8	4.13 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 28	26.05 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 8	2.46 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 12	6.35 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 18	13.11 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 34	33.87 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 40	39.34 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 48	43.20 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 48	31.15 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 34	28.69 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 40	30.00 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 18	9.40 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 12	3.28 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 8	0.00 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 28	20.49 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 12	3.39 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 28	5.00 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 40	6.78 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 34	5.08 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 48	9.84 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 18	3.33 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 8	0.00 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 12	1.64 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 48	33.85 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 18	1.67 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 28	1.75 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 40	23.08 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 34	19.67 Percentage of participants
Placebo	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 8	0.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 40	15.38 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 18	1.61 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 8	0.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 12	1.59 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 34	9.23 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 48	18.75 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48	Week 28	6.35 Percentage of participants

Secondary

Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. A SALT 75 response was a 75% or greater reduction from baseline in SALT score.

Time frame: Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point.

Arm	Measure	Group	Value (NUMBER)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	20.66 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	31.45 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	38.40 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	39.53 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	39.84 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	4.69 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	11.90 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	0.78 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	34.17 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	36.07 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	3.31 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	34.96 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	20.66 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	32.52 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	24.37 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	8.06 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	14.88 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	38.71 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	42.62 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	6.35 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	1.64 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	46.40 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	9.84 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	22.58 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	27.73 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	2.46 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	11.11 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	0.83 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	13.45 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	21.31 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	28.69 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	30.00 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	31.15 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	0.00 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	9.84 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	5.08 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	1.67 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	5.08 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	5.00 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	1.69 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	1.69 Percentage of participants
Placebo	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	1.54 Percentage of participants
Placebo	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	3.51 Percentage of participants
Placebo	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	1.59 Percentage of participants
Placebo	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	21.31 Percentage of participants
Placebo	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Placebo	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	32.31 Percentage of participants
Placebo	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	23.08 Percentage of participants
Placebo	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	1.64 Percentage of participants
Placebo	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	1.67 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	21.88 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	0.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	15.38 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	1.59 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	10.77 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	1.61 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	4.76 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	3.08 Percentage of participants

Secondary

Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

EBA is a numeric rating scale developed to characterize eyebrow hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where, 0= no eyebrow, 1=minimal eyebrow, 2=moderate eyebrow and 3= normal eyebrow, where higher scores represent less hair loss of eyebrows.

Time frame: Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point.

Arm	Measure	Group	Value (NUMBER)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	41.35 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	22.86 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	37.00 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	43.40 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	29.70 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	42.99 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	10.28 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	33.98 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	1.87 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	29.00 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	32.67 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	17.48 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	30.77 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	18.81 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	30.39 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	2.88 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	13.86 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	25.49 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	39.00 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	27.27 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	29.00 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	2.97 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	43.56 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	34.65 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	9.62 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	17.82 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	24.76 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	12.87 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	33.65 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	7.62 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	31.43 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	4.90 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	0.93 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	16.67 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	33.33 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	14.58 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	12.24 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	1.96 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	3.85 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	6.25 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	10.20 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	8.33 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	16.00 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	16.00 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	4.17 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	3.64 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	0.00 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	15.69 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	0.00 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	3.77 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	20.00 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	30.91 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	6.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	31.37 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	8.16 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	5.77 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	26.92 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	13.46 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	4.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	3.85 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	0.00 Percentage of participants

Secondary

Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

ELA is a numeric rating scale developed to characterize eyelash hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where, 0=no eyelash, 1=minimal eyelash, 2=moderate eyelash and 3=normal eyelash, where higher scores represent less hair loss of eyelash.

Time frame: Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point.

Arm	Measure	Group	Value (NUMBER)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	30.21 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	16.49 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	39.80 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	25.53 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	3.03 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	38.38 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	29.79 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	9.09 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	34.02 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	4.44 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	26.37 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	10.99 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	25.00 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	20.00 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	29.55 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	28.09 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	21.35 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	1.08 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	36.78 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	38.89 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	38.20 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	5.38 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	8.79 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	11.70 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	40.00 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	20.00 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	28.89 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	30.53 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	12.09 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	4.35 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	1.03 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	24.21 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	7.37 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	26.32 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	26.09 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	27.66 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	4.76 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	6.98 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	2.22 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	7.32 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	18.60 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	20.93 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	4.55 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	4.76 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	4.88 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	16.67 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	2.04 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	9.80 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	0.00 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	2.17 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	6.82 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	2.04 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	25.49 Percentage of participants
Placebo	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	37.25 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 24	0.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 48	35.56 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 40	17.39 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 18	0.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 12	0.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 8	0.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 4	0.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 34	6.52 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48	Week 28	4.55 Percentage of participants

Secondary

Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48

AAPPO scale is a 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over the past week. Items 1-4 were to assess the current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on a scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss', where higher scores indicated more hair loss.

Time frame: Week 4, 8, 12, 18, 24, 34, 40, and 48

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specified time point.

Arm	Measure	Group	Value (NUMBER)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on scalp	41.80 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on eyebrows	42.71 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on eyebrows	17.35 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on eyebrows	32.29 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on scalp	11.48 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on eyebrows	27.84 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on eyebrows	27.66 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on body	14.74 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on body	11.46 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on body	35.11 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on body	25.81 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on eyelashes	41.86 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on eyelashes	43.02 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on body	34.74 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on eyelashes	40.00 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on eyelashes	31.40 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on scalp	35.83 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on body	19.78 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on eyelashes	31.33 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on scalp	20.66 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on scalp	11.38 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on scalp	42.02 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on eyelashes	29.41 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on eyelashes	17.44 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on body	17.02 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on scalp	42.28 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on scalp	27.35 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on eyelashes	11.49 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on eyebrows	44.90 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on eyebrows	9.09 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on body	33.33 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on eyebrows	42.27 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on scalp	19.51 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on scalp	36.59 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on scalp	16.67 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on scalp	30.00 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on eyebrows	21.05 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on body	33.70 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on eyebrows	32.98 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on body	19.15 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on eyelashes	37.65 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on eyebrows	33.68 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on eyelashes	17.65 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on eyebrows	27.84 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on body	25.00 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on scalp	33.61 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on body	15.96 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on eyelashes	4.60 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on body	9.28 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on eyebrows	34.04 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on scalp	34.45 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on body	36.17 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on scalp	25.00 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on eyelashes	37.35 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on eyelashes	26.74 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on eyelashes	39.29 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on eyebrows	7.14 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on eyebrows	36.84 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on body	34.41 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on body	27.96 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on eyelashes	36.59 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on scalp	9.76 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on eyelashes	42.17 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on eyebrows	38.71 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on eyelashes	31.17 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on scalp	13.79 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on body	20.43 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on body	31.52 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on body	30.77 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on body	36.56 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on scalp	26.27 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on scalp	29.31 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on scalp	35.65 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on scalp	4.17 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on scalp	42.37 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on eyebrows	7.45 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on eyebrows	11.96 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on eyebrows	18.09 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on eyebrows	27.47 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on eyebrows	30.43 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on eyebrows	38.89 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on scalp	7.76 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on eyebrows	38.89 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on eyebrows	43.96 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on eyelashes	7.59 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on eyelashes	12.82 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on eyelashes	16.46 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on eyelashes	21.05 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on scalp	12.71 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on eyelashes	37.33 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on eyelashes	32.89 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on eyelashes	38.16 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on body	10.42 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on body	13.98 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on body	14.89 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on body	15.05 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on scalp	30.25 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on eyelashes	34.52 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on eyelashes	19.05 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on scalp	8.47 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on body	14.29 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on body	30.43 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on scalp	4.84 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on scalp	24.58 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on eyebrows	19.78 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on eyelashes	22.22 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on body	10.11 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on eyelashes	28.05 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on eyebrows	39.36 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on eyebrows	29.35 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on body	15.91 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on eyebrows	15.96 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on body	26.09 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on scalp	32.77 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on body	6.38 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on body	22.22 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on eyelashes	9.30 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on eyebrows	4.17 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on eyelashes	34.52 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on body	25.56 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on eyebrows	38.04 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on scalp	32.48 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on scalp	16.38 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on eyelashes	14.81 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on eyebrows	31.91 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on eyelashes	36.59 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on scalp	13.33 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on eyebrows	10.99 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on scalp	8.93 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on eyebrows	16.28 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on eyebrows	20.00 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on eyebrows	15.56 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on scalp	1.72 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on eyelashes	5.26 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on body	11.36 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on eyelashes	7.89 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on scalp	7.14 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on eyelashes	8.33 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on scalp	5.26 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on body	6.67 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on eyelashes	7.89 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on body	2.17 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on scalp	8.62 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on eyelashes	8.33 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on body	10.64 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on body	10.87 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on eyelashes	11.43 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on body	4.44 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on eyelashes	10.81 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on scalp	3.57 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on body	8.70 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on eyelashes	8.11 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on scalp	8.62 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on body	2.13 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on eyebrows	11.63 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on eyebrows	13.33 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on eyebrows	6.52 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on eyebrows	6.82 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on scalp	1.69 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on eyebrows	4.35 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on eyelashes	28.26 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on eyebrows	11.11 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on eyebrows	4.17 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on scalp	4.76 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on body	11.36 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on eyelashes	8.89 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on eyebrows	12.00 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on eyelashes	39.13 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on scalp	6.67 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on eyebrows	32.00 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on body	22.73 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on body	6.38 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on scalp	29.23 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on body	9.09 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on eyebrows	11.11 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on body	34.69 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on eyelashes	12.20 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on eyebrows	38.00 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on eyelashes	13.04 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on eyebrows	22.73 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on scalp	6.35 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on scalp	10.77 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on eyelashes	14.63 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on body	16.33 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on body	4.26 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on eyelashes	21.43 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on scalp	22.03 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on scalp	8.33 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on body	22.45 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on scalp	33.85 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on eyelashes	6.67 Percentage of participants
Placebo	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on eyebrows	6.25 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on body	20.45 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on scalp	3.17 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on scalp	8.06 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on scalp	4.92 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on scalp	6.78 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on scalp	6.35 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on scalp	11.29 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on scalp	19.05 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on scalp	20.97 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on eyebrows	8.70 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on eyebrows	11.11 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on eyebrows	6.82 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on eyebrows	7.14 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on eyebrows	10.87 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on eyebrows	13.33 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on eyebrows	23.91 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on eyebrows	33.33 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on eyelashes	5.26 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on eyelashes	8.11 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on eyelashes	8.33 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on eyelashes	2.94 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on eyelashes	2.63 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on eyelashes	13.51 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on eyelashes	13.16 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: current hair loss on eyelashes	28.95 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: current hair loss on body	11.36 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: current hair loss on body	11.63 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: current hair loss on body	7.14 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: current hair loss on body	7.50 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: current hair loss on body	11.36 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: current hair loss on body	9.30 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: current hair loss on body	11.36 Percentage of participants

Secondary

Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24

PGI-C is a self-administered questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. PGI-C was assessed on a 7-point Likert scale ranged from 1 (greatly improved) to 7 (greatly worsened). Categories were defined based on the PGI-C scores as follows: 1=greatly improved, 2=moderately improved, 3=slightly improved, 4=not changed, 5=slightly worsened, 6=moderately worsened and 7=greatly worsened.

Time frame: Week 24

Arm	Measure	Value (NUMBER)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24	52.19 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24	45.40 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24	49.17 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24	41.95 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24	11.36 Percentage of participants
Placebo	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24	9.23 Percentage of participants

p-value: <0.00000195% CI: [31.68, 54.25]Miettinen and Nurminen method

p-value: <0.00000195% CI: [25.22, 47.14]Miettinen and Nurminen method

p-value: <0.00000195% CI: [28.85, 51.06]Miettinen and Nurminen method

p-value: <0.00000195% CI: [21.95, 43.5]Miettinen and Nurminen method

Secondary

Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48

Time frame: Week 4, 8, 12, 18, 24, 34, 40, and 48

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point.

Arm	Measure	Group	Value (NUMBER)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: greatly improved	44.96 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: moderately improved	13.18 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: moderately improved	16.67 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: moderately improved	23.58 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: greatly improved	36.51 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: moderately improved	15.63 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: greatly improved	43.75 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: greatly improved	17.19 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: moderately improved	12.00 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: moderately improved	13.28 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: greatly improved	22.83 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: greatly improved	43.20 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: moderately improved	18.11 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: greatly improved	5.43 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: moderately improved	3.10 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: greatly improved	27.64 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: moderately improved	11.29 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: greatly improved	33.33 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: greatly improved	34.68 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: greatly improved	35.54 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: greatly improved	14.88 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: moderately improved	17.36 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: moderately improved	14.52 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: moderately improved	21.49 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: greatly improved	22.58 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: greatly improved	4.03 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: moderately improved	20.66 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: moderately improved	23.97 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: moderately improved	18.70 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: greatly improved	26.45 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: moderately improved	19.35 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: greatly improved	22.31 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: greatly improved	2.36 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: moderately improved	4.72 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: greatly improved	18.03 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: greatly improved	13.60 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: moderately improved	14.75 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: moderately improved	15.45 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: greatly improved	37.70 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: greatly improved	37.40 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: greatly improved	8.13 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: greatly improved	42.40 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: greatly improved	28.80 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: moderately improved	13.60 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: moderately improved	14.40 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: moderately improved	20.80 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: moderately improved	27.87 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: moderately improved	7.32 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: moderately improved	19.17 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: greatly improved	31.15 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: moderately improved	18.03 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: moderately improved	7.87 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: greatly improved	4.13 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: moderately improved	16.53 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: greatly improved	12.20 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: moderately improved	14.63 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: greatly improved	0 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: greatly improved	19.33 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: moderately improved	15.13 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: greatly improved	28.93 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: moderately improved	13.22 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: greatly improved	31.97 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: moderately improved	15.57 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: greatly improved	30.00 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: greatly improved	1.67 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: greatly improved	1.64 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: moderately improved	9.84 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: moderately improved	3.39 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: moderately improved	6.56 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: greatly improved	5.08 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: moderately improved	4.92 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: greatly improved	1.64 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: greatly improved	3.39 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: greatly improved	6.56 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: moderately improved	6.78 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: greatly improved	0 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: moderately improved	1.61 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: moderately improved	11.86 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: greatly improved	6.78 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: moderately improved	10.00 Percentage of participants
Placebo	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: greatly improved	1.54 Percentage of participants
Placebo	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: greatly improved	1.67 Percentage of participants
Placebo	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: greatly improved	0 Percentage of participants
Placebo	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: moderately improved	10.00 Percentage of participants
Placebo	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: greatly improved	30.77 Percentage of participants
Placebo	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: moderately improved	9.23 Percentage of participants
Placebo	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: moderately improved	22.03 Percentage of participants
Placebo	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: moderately improved	24.62 Percentage of participants
Placebo	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: greatly improved	0 Percentage of participants
Placebo	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: moderately improved	3.17 Percentage of participants
Placebo	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: greatly improved	42.19 Percentage of participants
Placebo	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: moderately improved	1.59 Percentage of participants
Placebo	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: greatly improved	18.64 Percentage of participants
Placebo	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: moderately improved	10.00 Percentage of participants
Placebo	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: greatly improved	1.59 Percentage of participants
Placebo	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: moderately improved	17.19 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: moderately improved	17.19 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: greatly improved	4.62 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: greatly improved	0 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 4: moderately improved	1.54 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: greatly improved	1.56 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 8: moderately improved	4.69 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: greatly improved	3.17 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 12: moderately improved	7.94 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: greatly improved	3.28 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 18: moderately improved	4.92 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 24: moderately improved	3.08 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: greatly improved	7.81 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 34: moderately improved	20.31 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: greatly improved	13.85 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 40: moderately improved	15.38 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48	Week 48: greatly improved	26.56 Percentage of participants

Other Pre-specified

Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48

HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for anxiety subscale; higher score indicating greater severity of anxiety symptoms. Baseline was defined as pre-dose on Day 1.

Time frame: Baseline (Day 1), Week 48

Arm	Measure	Group	Value (MEAN)	Dispersion
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Baseline	4.6 Units on a scale	Standard Deviation 3.84
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Change at Week 48	-1.0 Units on a scale	Standard Deviation 2.92
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Baseline	4.5 Units on a scale	Standard Deviation 3.18
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Change at Week 48	-0.8 Units on a scale	Standard Deviation 3.1
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Baseline	4.9 Units on a scale	Standard Deviation 3.31
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Change at Week 48	-0.8 Units on a scale	Standard Deviation 3.09
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Baseline	4.3 Units on a scale	Standard Deviation 3.42
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Change at Week 48	-0.5 Units on a scale	Standard Deviation 3.4
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Baseline	5.2 Units on a scale	Standard Deviation 3.38
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Change at Week 48	-1.2 Units on a scale	Standard Deviation 2.89
Placebo	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Baseline	5.3 Units on a scale	Standard Deviation 4.2
Placebo	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Change at Week 48	-1.3 Units on a scale	Standard Deviation 3.31
Placebo, Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Baseline	5.3 Units on a scale	Standard Deviation 3.7
Placebo, Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Change at Week 48	-0.5 Units on a scale	Standard Deviation 4.53

Other Pre-specified

Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24

Time frame: Baseline (Day 1), Week 4, 8, 12, and 24

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 12	-0.7 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 24	-0.8 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 4	-0.3 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 8	-0.8 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 24	-0.7 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 4	-0.4 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 8	-0.4 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 12	-0.9 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 8	-0.8 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 4	-0.4 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 12	-0.7 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 24	-0.8 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 24	-0.3 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 4	-0.5 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 8	-0.3 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 12	-0.3 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 4	-0.6 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 24	-1.0 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 12	-0.9 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 8	-0.9 Units on a scale
Placebo	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 24	-0.6 Units on a scale
Placebo	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 4	-0.1 Units on a scale
Placebo	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 8	-0.5 Units on a scale
Placebo	Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 12	-0.4 Units on a scale

Other Pre-specified

Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48

HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms. Baseline was defined as pre-dose on Day 1.

Time frame: Baseline (Day 1), Week 48

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point.

Arm	Measure	Group	Value (MEAN)	Dispersion
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Change at Week 48	-0.7 Units on a scale	Standard Deviation 2.13
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Baseline	2.7 Units on a scale	Standard Deviation 2.6
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Baseline	3.0 Units on a scale	Standard Deviation 3.16
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Change at Week 48	-0.4 Units on a scale	Standard Deviation 3.15
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Change at Week 48	-0.3 Units on a scale	Standard Deviation 2.67
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Baseline	2.9 Units on a scale	Standard Deviation 3
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Baseline	2.8 Units on a scale	Standard Deviation 2.99
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Change at Week 48	-0.6 Units on a scale	Standard Deviation 2.44
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Baseline	2.8 Units on a scale	Standard Deviation 2.8
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Change at Week 48	-0.5 Units on a scale	Standard Deviation 2.53
Placebo	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Change at Week 48	-0.9 Units on a scale	Standard Deviation 3.25
Placebo	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Baseline	3.2 Units on a scale	Standard Deviation 3.36
Placebo, Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Baseline	3.3 Units on a scale	Standard Deviation 3.54
Placebo, Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48	Change at Week 48	-0.4 Units on a scale	Standard Deviation 3.28

Other Pre-specified

Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24

HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms. Baseline was defined as pre-dose on Day 1.

Time frame: Baseline (Day 1), Week 4, 8, 12, and 24

Population: FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 4	-0.1 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 8	-0.5 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 12	-0.6 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 24	-0.4 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 12	-0.4 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 8	-0.3 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 4	-0.4 Units on a scale
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 24	-0.8 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 24	-0.3 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 12	0.0 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 8	-0.2 Units on a scale
Ritlecitinib (PF-06651600) 50 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 4	-0.1 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 4	-0.1 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 24	-0.2 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 8	0.2 Units on a scale
Ritlecitinib (PF-06651600) 30 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 12	0.1 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 12	-0.5 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 24	-0.4 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 8	-0.2 Units on a scale
Ritlecitinib (PF-06651600) 10 mg	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 4	-0.3 Units on a scale
Placebo	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 8	-0.3 Units on a scale
Placebo	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 12	-0.1 Units on a scale
Placebo	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 24	0.0 Units on a scale
Placebo	Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24	Change at Week 4	-0.3 Units on a scale

Other Pre-specified

Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48

HADS is a validated 14-item PRO measure used to assessed states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for anxiety subscale; higher score indicating greater severity of anxiety symptoms.

Time frame: Week 4, 8, 12, 24 and 48

Arm	Measure	Group	Value (NUMBER)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 12	50.00 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 4	51.72 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 48	53.85 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 8	46.43 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 24	51.85 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 12	57.89 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 8	50.00 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 24	65.00 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 4	45.45 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 48	66.67 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 48	60.00 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 8	68.00 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 4	34.62 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 12	38.46 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 24	50.00 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 12	56.25 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 4	37.50 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 8	41.67 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 24	46.67 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 48	50.00 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 4	40.00 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 48	61.54 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 12	42.86 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 24	57.14 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 8	71.43 Percentage of participants
Placebo	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 4	31.58 Percentage of participants
Placebo	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 48	57.89 Percentage of participants
Placebo	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 24	44.44 Percentage of participants
Placebo	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 8	33.33 Percentage of participants
Placebo	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 12	47.37 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 24	38.46 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 8	46.15 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 12	41.67 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 4	30.77 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 48	58.33 Percentage of participants

Other Pre-specified

Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48

HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms.

Time frame: Week 4, 8, 12, 24 and 48

Arm	Measure	Group	Value (NUMBER)
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 48	50.00 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 4	42.86 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 8	66.67 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 24	71.43 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 50 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 12	50.00 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 12	63.64 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 4	60.00 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 24	63.64 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 48	63.64 Percentage of participants
Ritlecitinib (PF-06651600) 200 mg Then 30 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 8	45.45 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 24	41.67 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 48	58.33 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 8	58.33 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 12	66.67 Percentage of participants
Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 4	53.85 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 24	42.86 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 48	46.15 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 4	42.86 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 8	33.33 Percentage of participants
Ritlecitinib (PF-06651600) 30 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 12	30.77 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 4	40.00 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 8	20.00 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 48	80.00 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 24	50.00 Percentage of participants
Ritlecitinib (PF-06651600) 10 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 12	20.00 Percentage of participants
Placebo	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 12	60.00 Percentage of participants
Placebo	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 24	50.00 Percentage of participants
Placebo	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 48	60.00 Percentage of participants
Placebo	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 8	50.00 Percentage of participants
Placebo	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 4	60.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 8	40.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 24	50.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 4	50.00 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 12	62.50 Percentage of participants
Placebo, Ritlecitinib (PF-06651600) 50 mg	Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48	Week 48	60.00 Percentage of participants

Source: ClinicalTrials.gov · Data processed: Jul 23, 2026

PF-06651600 for the Treatment of Alopecia Areata

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Other

Countries

Participant flow

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24

Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations

Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations

Change From Baseline in SALT Score at Week 28, 34, 40, and 48

Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24

Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model

Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model

Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1

Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4

Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48

Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48

Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48

Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24

Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48

Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48

Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24

Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48

Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24

Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48

Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48